SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

A significant market reaction to Anthropic's Claude Code, which automates COBOL modernization, is driving a sharp sell-off in IBM and the broader software sector. While many perceive this as a direct threat to IBM's legacy services, a vocal segment of the community views the move as an overreaction, pointing to IBM's existing partnership with Anthropic and its strong position in enterprise AI and hybrid cloud.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is actively discussed following its FDA approval of BYSANTI for bipolar I disorder and schizophrenia, a new chemical entity with patent protection extending to 2044. The community is buzzing about the stock's significant undervaluation, potential for a short squeeze, and mounting speculation around a major pharmaceutical buyout.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is experiencing a sharp decline following disappointing trial results for its next-generation obesity drug, CagriSema, which failed to demonstrate non-inferiority against Eli Lilly's rival treatment. Despite the market's strong negative reaction, many in the community believe the sell-off is an overreaction given the massive success of Novo's oral Wegovy pill and the company's perceived long-term value.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is experiencing intense volatility ahead of its upcoming Q4 earnings, as the stock is caught in a broader software sell-off driven by AI displacement fears, despite recent positive news like its WorkFusion acquisition and industry awards. While bears predict further declines amid general market weakness, the community is actively discussing strong institutional accumulation and the company's agentic AI leadership, with many viewing current prices as a significant buying opportunity.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal Holdings Inc. is trending due to widespread reports of potential takeover interest, with community chatter focusing on various major rivals as suitors and speculation regarding a fair acquisition price for the significantly undervalued fintech giant. Many are actively discussing the value of PayPal's assets, particularly Venmo, amidst hopes for a significant turnaround from recent stock performance.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending due to widespread panic selling across the software sector, fueled by concerns over AI's disruptive potential to traditional software models and the high costs associated with AI infrastructure, including for its partner OpenAI. This significant downturn has created a stark divide in community sentiment, with many viewing the current levels as a compelling buying opportunity while others anticipate further declines.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

A sector-wide sell-off in cybersecurity stocks is gripping Crowdstrike, as the market reacts to fears that Anthropic's new Claude Code Security tool could disrupt established solutions. The community is sharply divided, debating if this represents a genuine threat or an overblown reaction creating a buying opportunity, given Crowdstrike's distinct focus on endpoint and cloud security.

Mastercard, Inc. is a technology company, which engages in the provision of payment solutions for the development and implementation of credit, debit, prepaid, commercial, and payment programs through its brands including Mastercard, Maestro, and Cirrus. It also offers cyber and intelligence solutions. The company was founded in November 1966 and is headquartered in Purchase, NY.

Mastercard Incorporated - Ordinary Shares - Class A

Mastercard Inc

Mastercard is trending as a recent research report fuels investor fears that AI agents could disrupt its traditional payment business model by bypassing interchange fees, compounded by new global tariffs impacting cross-border transactions. The community is actively debating the long-term threat to payment networks, with some viewing it as panic-driven selling and others identifying a buying opportunity.

American Express Co. engages in the provision of card-issuing, merchant-acquiring, and card network businesses. Its products and services include credit cards, business credit cards, corporate programs, gift cards, savings accounts and CDs, and the American Express App. It operates through the following segments: the United States Consumer Services (USCS), Commercial Services (CS), International Card Services (ICS), Global Merchant and Network Services (GMNS), and Corporate and Other. The USCS segment includes proprietary consumer cards and provides services to United States consumers. The CS segment offers corporate and small business cards and provides services to United States businesses. The ICS segment provides consumers, small businesses, and corporate cards outside the United States. The GMNS segment is involved in operating a global payments network that processes and settles card transactions, acquires merchants, and provides multi-channel marketing programs and capabilities, services and data analytics. The Corporate and Other segment covers corporate functions and certain other businesses and operations. It also operates through the following geographical segments: United States, EMEA, APAC, LACC, and Other. The EMEA segment represents Europe, the Middle East, and Africa. The APAC segment refers to Asia Pacific, Australia, and New Zealand. The LACC segment focuses on Latin America, Canada, and the Caribbean. The Other segment includes net costs which are not directly allocated to specific geographic regions. The company was founded by Henry Wells, William G. Fargo, and John Warren Butterfield on March 28, 1850 and is headquartered in New York, NY.

American Express Co.

American Express is trending amidst widespread discussion of a proposed government-imposed cap on credit card interest rates, which is driving a broad sell-off across the payments sector. The community is sharply divided, with some expressing alarm over the downturn while others view it as an overblown reaction, highlighting AXP's premium customer base and seeing a buying opportunity.

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Redwood City MD.

Arcellx Inc

Arcellx Inc. is trending after Gilead Sciences announced an agreement to acquire the biotech for a significant premium, gaining full control of its promising BCMA CAR-T therapy, anito-cel. This news has ignited widespread investor excitement, driving ACLX shares sharply higher and fueling broader discussions about the valuation of innovative oncology assets in the current market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HC Wainwright Brokers Lift Earnings Estimates for KPTI

Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) - Equities researchers at HC Wainwright raised their Q1 2026 earnings per share (EPS) estimates for Karyopharm Therapeutics in a report issued...

Wall Street Analysts Believe Karyopharm Therapeutics (KPTI) Could Rally 56.06%: Here's is How to Trade

The consensus price target hints at a 56.1% upside potential for Karyopharm Therapeutics (KPTI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

HC Wainwright Reaffirms "Buy" Rating for Karyopharm Therapeutics (NASDAQ:KPTI)

HC Wainwright reaffirmed a "buy" rating and issued a $15.00 target price on shares of Karyopharm Therapeutics in a report on Wednesday...

Promising Nuclear Stocks To Consider - February 16th

Oklo, NuScale Power, Centrus Energy, BWX Technologies, Nano Nuclear Energy, Karyopharm Therapeutics, and Lightbridge are the seven Nuclear stocks to watch today, according to MarketBeat's stock...

Karyopharm Therapeutics (NASDAQ:KPTI) Announces Earnings Results, Misses Expectations By $3.45 EPS

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) announced its earnings results on Thursday. The company reported ($5.71) EPS for the quarter, missing the consensus estimate of ($2.26) by...

Karyopharm Therapeutics Q4 Earnings Call Highlights

Karyopharm Therapeutics (NASDAQ:KPTI) executives highlighted upcoming late-stage clinical catalysts, continued revenue growth for its multiple myeloma franchise, and a tighter cost structure during...

Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of +1.47% and +3.27%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Average Rating of "Moderate Buy" from Analysts

Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the seven research firms that are presently covering the stock, MarketBeat...

Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress

Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights...

Uncovering Potential: Karyopharm Therapeutics's Earnings Preview

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008, and is headquartered in Newton, MA.

Current Price	$10.00
Prev Close	$9.67
Open	$9.56
Dividend Yield	0.00%
50-Day Moving Average	$7.21
Beta	1.16
Avg. Volume	429,148.00
PE Ratio	-0.58

52-Week High	$10.38
52-Week Low	$3.51
Market Capitalization	$177.39M
EPS (Annual)	-$17.93
Price to Book	-0.60
Revenue Per Employee	$640,644.74

KPTI
Karyopharm Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest KPTI News

KPTIKaryopharm Therapeutics Inc